Sciwind Biosciences rallies $70m Series C

Sciwind Biosciences Co, a developer of new therapies to treat metabolic disease, has secured $70 million in Series C financing.

Sciwind Biosciences Co, a developer of new therapies to treat metabolic disease, has secured $70 million in Series C financing. IDG Capital, Loyal Valley Capital and LYFE Capital led the round.

Source: Press Release